长春高新(000661.SZ)下属公司签署GenSci098注射液项目独家许可协议

Core Viewpoint - Changchun Gaoxin has signed an exclusive licensing agreement for the GenSci098 injection project with Yarrow Bioscience, which is expected to generate significant upfront and milestone payments for the company [1] Group 1: Financial Aspects - The agreement includes an upfront payment of $70 million, which is non-refundable and non-offsettable, along with an additional $50 million in recent development milestone payments [1] - The total potential milestone payments that Changchun Gaoxin could receive from this exclusive license could reach up to $1.365 billion [1] - The company will also be entitled to receive over 10% of net sales as a sales commission once the product is launched [1] Group 2: Product Information - GenSci098 is a humanized monoclonal antibody that acts as an antagonist to the thyroid-stimulating hormone receptor (TSHR), developed by Jinsai Pharmaceutical [1] - The product is classified as a Class I new drug for therapeutic biological products and is aimed at treating conditions related to hyperthyroidism [1] - GenSci098 is currently being researched for its applications in treating thyroid eye disease (TED) and Graves' disease (GD) [1]